Craft

Walvax Biotechnology

Stock Price

¥15.7

2024-04-03

Market Capitalization

¥25.4 B

2024-04-03

Revenue

¥3.4 B

FY, 2021

Walvax Biotechnology Summary

Company Summary

Overview
Walvax Biotechnology (沃森生 生物技术, also known as Yunnan Watson Biotechnology, 云南沃森生物技术) is a company engaged in the research and development, production, and sales of human vaccines and biotechnology drugs. It offers valent pneumococcal polysaccharide conjugate vaccines, meningococcal polysaccharide vaccines, and other products.
Type
Public
Status
Active
Founded
2001
HQ
Kunming, CN | view all locations
Website
https://walvax.com
Cybersecurity rating
Sectors

Key People

  • Yunhua Wang, CFO

    LocationsView all

    1 location detected

    • Kunming, Yun Nan Sheng HQ

      China

      4th Floor, Building A3, Phase 2, Yunnan University Science and Technology Park, North District, High-tech Development Zone

    Walvax Biotechnology Financials

    Summary Financials

    Revenue (Q3, 2023)
    ¥988.0M
    Gross profit (Q3, 2023)
    ¥806.0M
    Net income (Q3, 2023)
    ¥134.7M
    Cash (Q3, 2023)
    ¥4.1B
    EBIT (Q3, 2023)
    ¥128.3M
    Enterprise value
    $21.9B

    Footer menu